Trial Profile
Comparison of Dapagliflozin and Pioglitazone Effects on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized,Open-Label, Active-Controlled Trial
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Sep 2018
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary) ; Pioglitazone (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics; Therapeutic Use
- 21 Sep 2018 Status changed from active, no longer recruiting to completed.
- 02 Jan 2018 New trial record